Status and phase
Conditions
Treatments
About
This is a Phase 3 Randomized Double-Blind Placebo-Controlled 6-month Parallel-Arm Study to Compare a Fixed Dose Combination of AD109 to Placebo in Obstructive Sleep Apnea.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Exclusion Criteria:
Primary purpose
Allocation
Interventional model
Masking
740 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Ron Farkas, MD; Luigi Taranto, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal